NCT00095992View on ClinicalTrials.gov

SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

March 8, 2005

Primary Completion Date

September 26, 2006

Study Completion Date

September 22, 2008

Conditions
Liver Cancer
Interventions
DRUG

ispinesib

SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks

Trial Locations (4)

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

K7L 5P9

Cancer Centre of Southeastern Ontario at Kingston, Kingston

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

NCIC Clinical Trials Group

NETWORK

NCT00095992 - SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer | Biotech Hunter | Biotech Hunter